Remove tag european
article thumbnail

STAT+: Kyowa Kirin to acquire Orchard Therapeutics, maker of gene therapy Libmeldy

STAT

Orchard, which has operations in London and Boston, has been one of the more successful companies at getting a gene therapy covered in European countries. Continue to STAT+ to read the full story…

112
112
article thumbnail

PharmaShots Weekly Snapshots (May 15 - 19, 2023)

PharmaShots

Alimera Acquires Rights from EyePoint Pharmaceuticals to Commercialise Yutiq in the US Date: May 19, 2023 | Tags: Alimera, EyePoint Pharmaceuticals, Yutiq, Iluvien, chronic non-infectious uveitis, US, Pharma Sobi Reports EMA’s Validation of MAA for Efanesoctocog Alfa to Treat Haemophilia A Date: May 19, 2023 | Tags: Sobi, Efanesoctocog Alfa, (..)

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Electronic smart packaging market to value nearly $3b in 2033

European Pharmaceutical Review

Yet apart from radio-frequency identification (RFID) tags and QR codes, adoption at scale has proved challenging overall, the report stated. Types of technologies such as wirelessly connected tags (active and passive) and sensors were also specified.

article thumbnail

Oligonucleotide synthesis market to reach $16.7 billion by 2027

European Pharmaceutical Review

Tag Copenhagen A/S (Denmark). billion by 2027 appeared first on European Pharmaceutical Review. Kaneka Corporation (Japan). Thermo Fisher Scientific, Inc. (US). Twist Bioscience Corporation (US). Maravai Life Sciences (US). Merck KGaA (Germany). Microsynth AG (Switzerland). Sarepta Therapeutics, Inc. (US).

article thumbnail

Benefits of blockchain in limiting counterfeit drug distribution

European Pharmaceutical Review

Smart contracts, which are essential for easing international trade and logistics operations, can enable the user to track fake returns to the producer and supplier using RFID tags. The post Benefits of blockchain in limiting counterfeit drug distribution appeared first on European Pharmaceutical Review.

88
article thumbnail

Can gene therapies for haemophilia defend their high price tags?

Pharmaceutical Technology

In the EU however, two years later, the European Commission awarded a conditional marketing authorisation for Roctavian. BioMarin previously said that the treatment’s European price would likely be around EUR1.5 The European Commission withdrew the marketing authorisation of Zynteglo, at the request of bluebird bio, in March 2022.

FDA 111
article thumbnail

Immunocore gets EU nod for TCR cancer therapy Kimmtrak

pharmaphorum

Immunocore now has approval on both side of the Atlantic for Kimmtrak – the first cancer therapeutic based on T cell receptor (TCR) technology – after getting a green light from the European Commission. The European population is meanwhile estimated at several thousand patients, across all stages, according to registry data.